Pre-made Fibatuzumab benchmark antibody ( Whole mAb, anti-EPHA3 therapeutic antibody, Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-211

Pre-Made Fibatuzumab biosimilar, Whole mAb, Anti-EPHA3 Antibody: Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Fibatuzumab is a humanised monoclonal antibody directed against the ephrin receptor A3 (EPHA3) , which is a receptor tyrosine kinase implicated in mediating nervous system development .

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-211-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Fibatuzumab biosimilar, Whole mAb, Anti-EPHA3 Antibody: Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 therapeutic antibody
INN Name Fibatuzumab
TargetEPHA3
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2017
CompaniesLudwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute
Conditions Approvedna
Conditions ActiveAcute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma
Conditions Discontinuedna
Development TechPOTELLIGENT Technology;Humaneering Technology